This is a randomized, double blinded, controlled phase I clinical study. To evaluate the safety and immunogenicity of receiving two doses of MVA strain monkeypox attenuated live vaccine in individuals aged 18 years and above.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Immediate adverse events
Timeframe: 60 minutes after each dose of vaccination
Solicited Adverse Events
Timeframe: 14 days after each dose of vaccination
Unsolicited Adverse Events
Timeframe: 28 or 30 days after each dose of vaccination
Abnormal incidence rate of electrocardiogram
Timeframe: 14 days after each dose of vaccination
Serious Adverse Events (SAE)
Timeframe: 12 months after the last dose
Adverse Event of Special Interest (AESI)
Timeframe: 12 months after the last dose